Smokers may be more likely to develop hearing loss than nonsmokers, and the risk increases with each additional cigarette people smoke on a typical day, a Japanese study suggests.
Deal activity is rampant as Big Pharma gobbles up next-generation medicines and technologies to help overcome maturing pipelines and biosimilar threats.
For the pharmaceutical industry, 2016 brought new blockbusters onto the market to ease the pain of patent expirations.
R&D success and M&A activity loom as large swing factors for the bio sector in 2017 with the regulatory arena potentially at its most amenable for years.
Nearly two decades ago, the promise of precision medicine began making its mark on the pages of medical journals – along with speculation that “therapy with the right drug at the right dose in the right patient” – would define the future of medical treatment.
There was a significant drop-off in NME approvals by FDA in 2016, but there were not enough new drug applications with user fee goals to reach the lofty 2015 total.
Auris Medical AG announced that the Swiss-based company’s Phase III tinnitus trial for Keyzilen failed to meet endpoints.
AbbVie and Neurocrine Biosciences announced that the Phase III ELARIS UF-II clinical trial of elagolix for uterine fibroids met its primary endpoint.
Gout sufferers with major pre-existing heart disease face a higher risk of death if they are treated with the drug febuxostat, a large long-term study has concluded.
In the past few years, personal fitness trackers have become all the rage. It’s fun to see your daily activity level, sleep quality and heart rate. But, does knowing this data lead to any positive changes?
Realm Therapeutics Inc.’s PR013 failed to show efficacy in its Phase II trial for allergic conjunctivitis.
Anthera Pharmaceuticals Inc. is evaluating all strategic options after the company’s lead drug failed in a late-stage trial, sending shares down 80 percent in premarket trading.
AstraZeneca expects a key lung cancer study of two immunotherapy drugs to produce overall survival results in the second half of 2018, rather than the first half.
Shares of MyoKardia climbed after the company revealed positive results from a mid-stage clinical trial for obstructive hypertrophic cardiomyopathy.
Sanofi and Evotec started exclusive talks over accelerating research into the treatment of infectious diseases and will form a new open innovation platform in this area, led by Evotec.
Eisai and Merck agreed upon a strategic collaboration for the worldwide co-development and co-commercialization of Lenvima (lenvatinib mesylate), an orally available tyrosine kinase inhibitor.
Esperion Therapeutics Inc. said a late-stage trial of the company’s experimental oral drug met the main goal of reducing cholesterol by 28 percent in patients suffering from, or at a high risk of, an artery-clogging heart disease.
Vanda Pharmaceuticals, Inc., based in Washington, D.C., announced positive results from its JET8 Phase III clinical trial of Hetlioz for jet lag disorder.
Dermira Inc. will discontinue development of the company’s acne drug after the experimental treatment failed to meet the main goals of two late-stage studies.
Clearside Biomedical Inc. said the drug developer’s treatment helped improve vision in patients with fluid buildup in the eye in a late-stage study.
Santhera Pharmaceuticals said a study of the Swiss drug company’s medicine Raxone in primary progressive multiple sclerosis showed no difference between the treatment and placebo groups in disease progression.
Roche and Ionis Pharmaceuticals touted biomarker data from an early-stage study that showed IONIS-HTTRx lowered the disease-causing protein in people with Huntington’s disease.
French company DBV Technologies said its Viaskin Milk product yielded successful results in a Phase II trial for patients suffering from IgE-mediated cow’s milk protein allergy.
Cardiac arrest patients may be more likely to survive and avoid permanent disabilities when bystanders use a defibrillator to treat them before an ambulance arrives, a new study suggests.
Eli Lilly published results from a new Phase IIIb study of Trulicity (dulaglutide) in combination with a SGLT-2 inhibitor showing improved blood sugar control in adults with type 2 diabetes.